Product Pipeline
Cancer has been a core disease focus since the company’s inception. Corixa is engaged in discovery of antigens from the world's most widespread cancers, including lymphoma; melanoma; breast, prostate, lung, colon and ovarian carcinoma; and leukemia. According to the American Cancer Society, cancer is the second leading cause of death in the U.S. and since 1990, 13 million new cancer cases have been diagnosed. Most cancer patients undergo chemotherapy, radiation therapy and surgery, yet most patients are likely to relapse with malignant disease within 10 years following such therapies. Corixa believes that its vaccines and therapeutic antibodies will be most efficacious in those patients who have undergone prior therapy to reduce tumor burden.

Products on the Market
MELACINE for melanoma (in Canada)
Products in Clinical Trials
BEXXAR therapy for NHL
ENHANZYN adjuvant for breast cancer
MELACINE vaccine for melanoma
ENHANZYN adjuvant for colorectal cancer
Her-2/neu for breast/ovarian cancer
vaccine for lung cancer
A business overview as well as information on Corixa's partners, management team, employment opportunities, and company contacts.
Corixa's products and adjuvants for research applications.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.
Company reports, SEC filings, events calendar, stock quote, analyst list, and materials request.
Current and archived company press releases.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.